Clinical trial
Phase 1 Study of CPX-351(Cytarabine:Daunorubicin) Liposome Injection in Patients With Advanced Hematologic Malignancies.
NCT00389428 is registered in ClinicalTrials.gov with Jazz Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase 1 Study of CPX-351(Cytarabine:Daunorubicin) Liposome Injection in Patients With Advanced Hematologic Malignancies.
- Lead sponsor
- Jazz Pharmaceuticals
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- September 30, 2006
- Completion date
- December 31, 2009
- Enrollment
- 48 (actual)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.